ABSTRACT
The rapid physical maturation that occurs between birth and adulthood is well known. Logically, it would be anticipated that these changes would result in altered responses to xenobiotics. Within the first 5 years of life 95% of children have been prescribed medications. Yet in 1977 only one third of the new molecular entities that have potential usefulness in pediatric patients had pediatric labeling at the time of approval.
